- Home
- FLYE vs KZIA Comparison
FLYE vs KZIA Comparison
Compare FLYE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | KZIA |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 186.7M |
| IPO Year | 2024 | 2002 |
Fundamental Metrics
Financial Performance| Metric | FLYE | KZIA |
|---|---|---|
| Price | $2.66 | $7.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | ★ 4.7M | 257.3K |
| Earning Date | 09-01-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,063,357.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $4.86 |
| 52 Week High | $109.00 | $17.40 |
Technical Indicators
Market Signals| Indicator | FLYE | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 29.26 |
| Support Level | $1.55 | $6.82 |
| Resistance Level | $11.50 | $8.18 |
| Average True Range (ATR) | 0.84 | 0.62 |
| MACD | 0.20 | -0.12 |
| Stochastic Oscillator | 28.49 | 23.78 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. It offers 27 E-motorcycle products, 37 E-bike products and 38 E-scooter products.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.